| abstract |
The present disclosure relates to methods for treating or inhibiting tumor growth, wherein the methods comprise selecting an individual having skin cancer and intralesionally administering a therapeutically effective amount of a programmed death 1(PD-1) inhibitor (e.g., an antibody or antigen-binding fragment thereof that specifically binds PD-1, PD-L1, and/or PD-L2) to a tumor of an individual in need thereof. In some embodiments, the skin cancer is a cutaneous squamous cell carcinoma. In some embodiments, the PD-1 inhibitor is administered into multiple locations of a tumor lesion. |